Establishment of the National Clinical Care Commission and Solicitation of Nominations for Commission Members, 18314-18316 [2018-08797]
Download as PDF
<![CDATA[
amozie on DSK30RV082PROD with NOTICES
18314
Federal Register / Vol. 83, No. 81 / Thursday, April 26, 2018 / Notices
46. Argelio Garcia, North Bend,
Washington, Court of Federal
Claims No: 18–0401V
47. Jo Ann Gilbert, Pennsville, New
Jersey, Court of Federal Claims No:
18–0402V
48. Travis Eason, Montgomery,
Alabama, Court of Federal Claims
No: 18–0406V
49. Sean Kaplan, Chicago, Illinois, Court
of Federal Claims No: 18–0407V
50. Amarachi Grace Otuokere, Austin,
Texas, Court of Federal Claims No:
18–0409V
51. Shelle Johnson, Chatfield,
Minnesota, Court of Federal Claims
No: 18–0410V
52. Amber Etheridge, Tuscaloosa,
Alabama, Court of Federal Claims
No: 18–0411V
53. Mary E. Lyons, Seattle, Washington,
Court of Federal Claims No: 18–
0414V
54. Christian Park, Dothan, Alabama,
Court of Federal Claims No: 18–
0415V
55. Jennifer Talbot, South Weymouth,
Massachusetts, Court of Federal
Claims No: 18–0416V
56. Joy Houston, New Orleans,
Louisiana, Court of Federal Claims
No: 18–0420V
57. Kristian M. Ellingsen, Sterling,
Virginia, Court of Federal Claims
No: 18–0421V
58. Harry D. Tanner, Jr., Monroe, North
Carolina, Court of Federal Claims
No: 18–0422V
59. Philip Arcadipane, Brockton,
Massachusetts, Court of Federal
Claims No: 18–0423V
60. Keith McCarville, Newton, Iowa,
Court of Federal Claims No: 18–
0424V
61. Sharon Rons, Sioux Falls, South
Dakota, Court of Federal Claims No:
18–0425V
62. Mary George, Boston, Massachusetts,
Court of Federal Claims No: 18–
0426V
63. Sandra Posh-Denzler, Stratford,
Connecticut, Court of Federal
Claims No: 18–0427V
64. Richard Chester, Minocqua,
Wisconsin, Court of Federal Claims
No: 18–0428V
65. Rebekah Morgan, Henderson,
Nevada, Court of Federal Claims
No: 18–0429V
66. Ruby Katherine Gordon on behalf of
C.C., Kings Mountain, North
Carolina, Court of Federal Claims
No: 18–0431V
67. Dawn Eberhardt, Madison,
Wisconsin, Court of Federal Claims
No: 18–0432V
68. Rufus D. Parker, Shelby, North
Carolina, Court of Federal Claims
No: 18–0434V
VerDate Sep<11>2014
16:58 Apr 25, 2018
Jkt 244001
69. Miranda Sellers, Washington,
District of Columbia, Court of
Federal Claims No: 18–0435V
70. John Bayles, Washington, District of
Columbia, Court of Federal Claims
No: 18–0436V
71. Louie Garcia, Washington, District of
Columbia, Court of Federal Claims
No: 18–0438V
72. Gail Linville, Washington, District of
Columbia, Court of Federal Claims
No: 18–0439V
73. A L V and M V on behalf of AA—
VV, Park Ridge, Illinois, Court of
Federal Claims No: 18–0440V
74. Tiffany Dagen, Middletown,
Pennsylvania, Court of Federal
Claims No: 18–0442V
75. Sharon Gregory, Durham, North
Carolina, Court of Federal Claims
No: 18–0444V
76. Denise Bigda, Boston,
Massachusetts, Court of Federal
Claims No: 18–0445V
77. Virginia Wilt, Norristown,
Pennsylvania, Court of Federal
Claims No: 18–0446V
78. Spencer Vick, Fayetteville, Georgia,
Court of Federal Claims No: 18–
0447V
79. Kevin Randall, Haddonfield, New
Jersey, Court of Federal Claims No:
18–0448V
80. Karen Owens, Gainesville, Florida,
Court of Federal Claims No: 18–
0449V
81. Noah E. Musick, Greensboro, North
Carolina, Court of Federal Claims
No: 18–0451V
82. Zina Sanders, Tampa, Florida, Court
of Federal Claims No: 18–0452V
83. Linda D. Kooker, Erie, Pennsylvania,
Court of Federal Claims No: 18–
0453V
84. Vincent Ricciardi, Deer Park, New
York, Court of Federal Claims No:
18–0455V
85. Raine Learn, Corning, New York,
Court of Federal Claims No: 18–
0456V
86. Laura Russell, Dresher,
Pennsylvania, Court of Federal
Claims No: 18–0457V
87. Jodi Mickelson, Clarion, Iowa, Court
of Federal Claims No: 18–0459V
88. Chelsea Engel on behalf of A.E.,
Dresher, Pennsylvania, Court of
Federal Claims No: 18–0461V
89. Leonard E Smith, Greensboro, North
Carolina, Court of Federal Claims
No: 18–0462V
90. Charla Thornton, Washington,
District of Columbia, Court of
Federal Claims No: 18–0464V
91. Patricia Kelley, Washington, District
of Columbia, Court of Federal
Claims No: 18–0466V
92. Richard Proctor, Washington,
District of Columbia, Court of
Federal Claims No: 18–0468V
PO 00000
Frm 00053
Fmt 4703
Sfmt 4703
93. Barbara Plowman, Knoxville,
Tennessee, Court of Federal Claims
No: 18–0469V
94. Kelly Dean, Lancaster, Ohio, Court
of Federal Claims No: 18–0470V
95. Rita Czyzewski, Berlin, New Jersey,
Court of Federal Claims No: 18–
0471V
96. Philip Yeakel, Washington, District
of Columbia, Court of Federal
Claims No: 18–0472V
97. Benjamin Taylor, Dresher,
Pennsylvania, Court of Federal
Claims No: 18–0473V
[FR Doc. 2018–08715 Filed 4–25–18; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Establishment of the National Clinical
Care Commission and Solicitation of
Nominations for Commission Members
Office of Disease Prevention
and Health Promotion, Office of the
Assistant Secretary for Health, Office of
the Secretary, U.S. Department of Health
and Human Services.
ACTION: Notice.
AGENCY:
The U.S. Department of
Health and Human Services (HHS)
hereby announces the establishment of
the National Clinical Care Commission
(the Commission) pursuant to the
National Clinical Care Commission Act.
The Commission will consist of
representatives of specific federal
agencies and non-federal individuals
and entities who represent diverse
disciplines and views. The Commission
will evaluate and make
recommendations to the HHS Secretary
and Congress regarding improvements
to the coordination and leveraging of
federal programs related to awareness
and clinical care for complex metabolic
or autoimmune diseases that result from
issues related to insulin that represent a
significant disease burden in the United
States, which may include
complications due to such diseases.
Through this notice, HHS is also
requesting nominations of individuals
who are interested in being considered
for appointment to the Commission.
Resumes or curricula vitae from
qualified individuals who wish to be
considered for appointment as a
member of the Commission are
currently being accepted.
DATES: Nominations must be received
no later than close of business May 29,
2018.
ADDRESSES: Qualified persons and
interested organizations are invited to
SUMMARY:
E:\FR\FM\26APN1.SGM
26APN1
Federal Register / Vol. 83, No. 81 / Thursday, April 26, 2018 / Notices
submit nominations by any of the
following methods:
• Email: OHQ@hhs.gov (please
indicate in the subject line: National
Clinical Care Commission)
• Mail/Courier: Office of Disease
Prevention and Health Promotion, Attn:
Division of Health Care Quality,
Department of Health and Human
Services, 1101 Wootton Parkway, Suite
LL100, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT:
Clydette Powell, MD, MPH, FAAP,
Director, Division of Health Care
Quality, Office of Disease Prevention
and Health Promotion, Office of the
Assistant Secretary for Health; U.S.
Department of Health and Human
Services; Telephone: 240–453–8239;
Email address: OHQ@hhs.gov (please
indicate in the subject line: National
Clinical Care Commission). The
Commission charter may be accessed
online at https://health.gov/hcq/
national-clinical-care-commission.asp.
The charter includes detailed
information about the purpose,
function, and structure of the
Commission.
The
National Clinical Care Commission Act
(Pub. L. 115–80) requires the HHS
Secretary to establish the National
Clinical Care Commission. The
Commission will consist of
representatives of specific federal
agencies and non-federal individuals
and entities who represent diverse
disciplines and views. The Commission
will evaluate and make
recommendations to the HHS Secretary
and Congress regarding improvements
to the coordination and leveraging of
federal programs related to awareness
and clinical care for complex metabolic
or autoimmune diseases that result from
issues related to insulin that represent a
significant disease burden in the United
States, which may include
complications due to such diseases.
Objectives and Scope of Activities.
The Commission shall evaluate and
make recommendations, as appropriate,
to the Secretary and Congress regarding:
(1) Federal programs of the
Department of Health and Human
Services that focus on preventing and
reducing the incidence of complex
metabolic or autoimmune diseases
resulting from issues related to insulin
that represent a significant disease
burden in the United States, which may
include complications due to such
diseases;
(2) Current activities and gaps in
federal efforts to support clinicians in
providing integrated, high-quality care
amozie on DSK30RV082PROD with NOTICES
SUPPLEMENTARY INFORMATION:
VerDate Sep<11>2014
16:58 Apr 25, 2018
Jkt 244001
to individuals with the diseases and
complications;
(3) The improvement in, and
improved coordination of, federal
education and awareness activities
related to the prevention and treatment
of the diseases and complications,
which may include the utilization of
new and existing technologies;
(4) Methods for outreach and
dissemination of education and
awareness materials that—
(a) address the diseases and
complications;
(b) are funded by the federal
government; and
(c) are intended for health care
professionals and the public; and
(5) Whether there are opportunities
for consolidation of inappropriately
overlapping or duplicative federal
programs related to the diseases and
complications.
Membership and Designation. The
Commission shall consist of 23 voting
members. The composition shall
include eleven ex-officio members and
twelve non-federal members. The exofficio members shall consist of the
heads of, or subordinate officials
designated by the heads of, the
following federal departments, agencies,
or components: The Centers for
Medicare and Medicaid Services, the
Agency for Healthcare Research and
Quality, the Centers for Disease Control
and Prevention, the Indian Health
Service, the National Institutes of
Health, the Food and Drug
Administration, the Health Resources
and Services Administration, the Office
of Minority Health, the Department of
Defense, the Department of Veterans
Affairs, and the Department of
Agriculture.
The twelve non-federal members shall
be appointed as special government
employees (SGEs) by the Secretary and
shall have expertise in prevention, care,
and epidemiology of any of the diseases
and complications described in Section
2(a) of the National Clinical Care
Commission Act. The non-federal
members shall include one or more
members from each of the following
categories: Physician specialties,
including clinical endocrinologists, that
play a role in the prevention or
treatment of diseases and complications;
primary care physicians; non-physician
health care professionals; patient
advocates; national experts, including
public health experts; and health care
providers furnishing services to a
patient population that consists of a
high percentage (as specified by the
Secretary) of individuals who are
enrolled in a state plan under title XIX
of the Social Security Act or who are not
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
18315
covered under a health plan or health
insurance coverage. One of the nonfederal members shall be selected by the
members to serve as the Chair.
The ex-officio members and nonfederal members shall be appointed to
serve for the duration of the time that
the Commission is authorized to
operate. Any vacancy of a non-federal
member shall be filled in the same
manner as the original appointments.
Any non-federal member who is
appointed to fill the vacancy of an
unexpired term shall be appointed to
serve for the remainder of that term.
Pursuant to advance written
agreement, each non-federal member of
the Commission will waive his or her
right to compensation for performing
services as a member of the
Commission. However, non-federal
members shall receive per diem and
reimbursement for travel expenses
incurred in relation to performing duties
for the Commission, as authorized by
FACA and 5 U.S.C. 5703 for persons
who are employed intermittently to
perform services for the Federal
government and in accordance with
federal travel regulations. Ex-officio
members of the Commission remain
covered under their current
compensation system.
Estimated Number and Frequency of
Meetings. The Commission shall meet at
least twice and not more than four times
a year. These meetings may be in person
or conducted by teleconference or
videoconference at the discretion of the
Designated Federal Official (DFO). The
meetings shall be open to the public,
except as determined otherwise by the
Secretary, or other official to whom
authority has been delegated, in
accordance with the guidelines under
Government in the Sunshine Act, 5
U.S.C. 552b(c). Notice of all meetings
shall be provided to the public in
accordance with the FACA. Meetings
shall be conducted and records of the
proceedings shall be kept, as required
by applicable laws and departmental
policies. A quorum is required for the
Commission to meet to conduct
business. A quorum shall consist of a
majority of the Commission’s voting
members.
When the Secretary or designee
determines that a meeting shall be
closed or partially closed to the public,
in accordance with stipulations of
Government in the Sunshine Act, 5
U.S.C. 552b(c), then a report shall be
prepared by the DFO that includes, at a
minimum, a list of members and their
business addresses, the Commission’s
functions, date and place of the meeting,
and a summary of the Commission’s
activities and recommendations made
E:\FR\FM\26APN1.SGM
26APN1
18316
Federal Register / Vol. 83, No. 81 / Thursday, April 26, 2018 / Notices
amozie on DSK30RV082PROD with NOTICES
during the fiscal year. A copy of the
report will be provided to the
Department’s Committee Management
Officer.
Nominations. Nominations, including
self-nominations, of individuals who
have the specified expertise and
knowledge will be considered for
appointment as members of the
Commission. A nomination should
include, at a minimum, the following
for each nominee: (1) A letter of
nomination that clearly states the name
and affiliation of the nominee, the basis
for the nomination, and a statement
from the nominee that indicates that the
individual is willing to serve as a
member of the Commission, if selected;
(2) a one-page biography that describes
the nominee’s qualifications and, if
applicable, highlights relevant
experience on other federal advisory
committees; (3) the nominator’s name,
address, and daytime telephone
number; and the address, telephone
number, and email address of the
individual being nominated; and (4) a
current copy of the nominee’s
curriculum vitae or resume, which
should be limited to no more than 30
pages. Incomplete nomination packages
will not be reviewed.
Every effort will be made to ensure
that the composition of the Commission
includes individuals from various
geographic locations, including rural
and underserved areas; racial and ethnic
minorities; genders, and persons living
with disabilities. Individuals other than
officers or employees of the United
States government being considered for
appointment as members of the
Commission will be required to
complete and submit a report of their
financial holdings. An ethics review
must be conducted to ensure that
individuals appointed as members of
the Commission are not involved in any
activity that may pose a potential
conflict of interest for the official duties
that are to be performed. This is a
federal ethics requirement that must be
satisfied upon entering the position and
annually throughout the established
term of appointment on the
Commission.
Authority: The National Clinical Care
Commission Act (Pub. L. 115–80) requires
establishment of the National Clinical Care
Commission. The Commission is governed by
provisions of the Federal Advisory
Committee Act, Public Law 92–463, as
amended (5 U.S.C. App.), which sets forth
standards for the formation and use of federal
advisory committees.
VerDate Sep<11>2014
16:58 Apr 25, 2018
Jkt 244001
Dated: April 19, 2018.
Don Wright,
Deputy Assistant Secretary for Health
(Disease Prevention and Health Promotion).
[FR Doc. 2018–08797 Filed 4–25–18; 8:45 am]
BILLING CODE 4150–32–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Meeting of the Presidential Advisory
Council on Combating AntibioticResistant Bacteria
Office of the Assistant
Secretary for Health, Office of the
Secretary, Department of Health and
Human Services.
ACTION: Notice.
AGENCY:
As stipulated by the Federal
Advisory Committee Act, the
Department of Health and Human
Services (HHS) is hereby giving notice
that a meeting is scheduled to be held
for the Presidential Advisory Council on
Combating Antibiotic-Resistant Bacteria
(Advisory Council). The meeting will be
open to the public; a public comment
session will be held during the meeting.
Pre-registration is required for members
of the public who wish to attend the
meeting and who wish to participate in
the public comment session. Individuals
who wish to attend the meeting and/or
send in their public comment via email
should send an email to CARB@hhs.gov.
Registration information is available on
the website https://www.hhs.gov/ash/
carb/ and must be completed by May 9,
2018; all in-person attendees must preregister by this date. Additional
information about registering for the
meeting and providing public comment
can be obtained at https://www.hhs.gov/
ash/carb/ on the Meetings page.
DATES: The meeting is scheduled to be
held on May 16, 2018, from 9:00 a.m. to
4:45 p.m. ET (times are tentative and
subject to change). The confirmed times
and agenda items for the meeting will be
posted on the website for the Advisory
Council at https://www.hhs.gov/ash/
carb/ when this information becomes
available. Pre-registration for attending
the meeting in person is required to be
completed no later than May 9, 2018;
public attendance at the meeting is
limited to the available space.
ADDRESSES: U.S. Department of Health
and Human Services, Hubert H.
Humphrey Building, Great Hall, 200
Independence Avenue SW, Washington,
DC 20201.
The meeting can also be accessed
through a live webcast on the day of the
meeting. For more information,
SUMMARY:
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
FOR FURTHER INFORMATION CONTACT:
Jomana Musmar, Acting Designated
Federal Officer, Presidential Advisory
Council on Combating AntibioticResistant Bacteria, Office of the
Assistant Secretary for Health, U.S.
Department of Health and Human
Services, Room 715H, Hubert H.
Humphrey Building, 200 Independence
Avenue, SW, Washington, DC 20201.
Phone: (202) 690–5566; email: CARB@
hhs.gov.
Under
Executive Order 13676, dated
September 18, 2014, authority was given
to the Secretary of HHS to establish the
Advisory Council, in consultation with
the Secretaries of Defense and
Agriculture. Activities of the Advisory
Council are governed by the provisions
of Public Law 92–463, as amended (5
U.S.C. App.), which sets forth standards
for the formation and use of federal
advisory committees.
The Advisory Council will provide
advice, information, and
recommendations to the Secretary of
HHS regarding programs and policies
intended to support and evaluate the
implementation of Executive Order
13676, including the National Strategy
for Combating Antibiotic-Resistant
Bacteria and the National Action Plan
for Combating Antibiotic-Resistant
Bacteria. The Advisory Council shall
function solely for advisory purposes.
In carrying out its mission, the
Advisory Council will provide advice,
information, and recommendations to
the Secretary regarding programs and
policies intended to preserve the
effectiveness of antibiotics by
optimizing their use; advance research
to develop improved methods for
combating antibiotic resistance and
conducting antibiotic stewardship;
strengthen surveillance of antibioticresistant bacterial infections; prevent
the transmission of antibiotic-resistant
bacterial infections; advance the
development of rapid point-of-care and
agricultural diagnostics; further research
on new treatments for bacterial
infections; develop alternatives to
antibiotics for agricultural purposes;
maximize the dissemination of up-todate information on the appropriate and
proper use of antibiotics to the general
public and human and animal
healthcare providers; and improve
international coordination of efforts to
combat antibiotic resistance.
The May 16, 2018, public meeting
will be focused on the topic of antibiotic
stewardship for animal and plant
health. The meeting agenda will be
posted on the Advisory Council website
at https://www.hhs.gov/ash/carb/ when it
SUPPLEMENTARY INFORMATION:
E:\FR\FM\26APN1.SGM
26APN1
]]>Agencies
[Federal Register Volume 83, Number 81 (Thursday, April 26, 2018)]
[Notices]
[Pages 18314-18316]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-08797]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Establishment of the National Clinical Care Commission and
Solicitation of Nominations for Commission Members
AGENCY: Office of Disease Prevention and Health Promotion, Office of
the Assistant Secretary for Health, Office of the Secretary, U.S.
Department of Health and Human Services.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The U.S. Department of Health and Human Services (HHS) hereby
announces the establishment of the National Clinical Care Commission
(the Commission) pursuant to the National Clinical Care Commission Act.
The Commission will consist of representatives of specific federal
agencies and non-federal individuals and entities who represent diverse
disciplines and views. The Commission will evaluate and make
recommendations to the HHS Secretary and Congress regarding
improvements to the coordination and leveraging of federal programs
related to awareness and clinical care for complex metabolic or
autoimmune diseases that result from issues related to insulin that
represent a significant disease burden in the United States, which may
include complications due to such diseases.
Through this notice, HHS is also requesting nominations of
individuals who are interested in being considered for appointment to
the Commission. Resumes or curricula vitae from qualified individuals
who wish to be considered for appointment as a member of the Commission
are currently being accepted.
DATES: Nominations must be received no later than close of business May
29, 2018.
ADDRESSES: Qualified persons and interested organizations are invited
to
[[Page 18315]]
submit nominations by any of the following methods:
Email: [email protected] (please indicate in the subject line:
National Clinical Care Commission)
Mail/Courier: Office of Disease Prevention and Health
Promotion, Attn: Division of Health Care Quality, Department of Health
and Human Services, 1101 Wootton Parkway, Suite LL100, Rockville, MD
20852.
FOR FURTHER INFORMATION CONTACT: Clydette Powell, MD, MPH, FAAP,
Director, Division of Health Care Quality, Office of Disease Prevention
and Health Promotion, Office of the Assistant Secretary for Health;
U.S. Department of Health and Human Services; Telephone: 240-453-8239;
Email address: [email protected] (please indicate in the subject line:
National Clinical Care Commission). The Commission charter may be
accessed online at https://health.gov/hcq/national-clinical-care-commission.asp. The charter includes detailed information about the
purpose, function, and structure of the Commission.
SUPPLEMENTARY INFORMATION: The National Clinical Care Commission Act
(Pub. L. 115-80) requires the HHS Secretary to establish the National
Clinical Care Commission. The Commission will consist of
representatives of specific federal agencies and non-federal
individuals and entities who represent diverse disciplines and views.
The Commission will evaluate and make recommendations to the HHS
Secretary and Congress regarding improvements to the coordination and
leveraging of federal programs related to awareness and clinical care
for complex metabolic or autoimmune diseases that result from issues
related to insulin that represent a significant disease burden in the
United States, which may include complications due to such diseases.
Objectives and Scope of Activities. The Commission shall evaluate
and make recommendations, as appropriate, to the Secretary and Congress
regarding:
(1) Federal programs of the Department of Health and Human Services
that focus on preventing and reducing the incidence of complex
metabolic or autoimmune diseases resulting from issues related to
insulin that represent a significant disease burden in the United
States, which may include complications due to such diseases;
(2) Current activities and gaps in federal efforts to support
clinicians in providing integrated, high-quality care to individuals
with the diseases and complications;
(3) The improvement in, and improved coordination of, federal
education and awareness activities related to the prevention and
treatment of the diseases and complications, which may include the
utilization of new and existing technologies;
(4) Methods for outreach and dissemination of education and
awareness materials that--
(a) address the diseases and complications;
(b) are funded by the federal government; and
(c) are intended for health care professionals and the public; and
(5) Whether there are opportunities for consolidation of
inappropriately overlapping or duplicative federal programs related to
the diseases and complications.
Membership and Designation. The Commission shall consist of 23
voting members. The composition shall include eleven ex-officio members
and twelve non-federal members. The ex-officio members shall consist of
the heads of, or subordinate officials designated by the heads of, the
following federal departments, agencies, or components: The Centers for
Medicare and Medicaid Services, the Agency for Healthcare Research and
Quality, the Centers for Disease Control and Prevention, the Indian
Health Service, the National Institutes of Health, the Food and Drug
Administration, the Health Resources and Services Administration, the
Office of Minority Health, the Department of Defense, the Department of
Veterans Affairs, and the Department of Agriculture.
The twelve non-federal members shall be appointed as special
government employees (SGEs) by the Secretary and shall have expertise
in prevention, care, and epidemiology of any of the diseases and
complications described in Section 2(a) of the National Clinical Care
Commission Act. The non-federal members shall include one or more
members from each of the following categories: Physician specialties,
including clinical endocrinologists, that play a role in the prevention
or treatment of diseases and complications; primary care physicians;
non-physician health care professionals; patient advocates; national
experts, including public health experts; and health care providers
furnishing services to a patient population that consists of a high
percentage (as specified by the Secretary) of individuals who are
enrolled in a state plan under title XIX of the Social Security Act or
who are not covered under a health plan or health insurance coverage.
One of the non-federal members shall be selected by the members to
serve as the Chair.
The ex-officio members and non-federal members shall be appointed
to serve for the duration of the time that the Commission is authorized
to operate. Any vacancy of a non-federal member shall be filled in the
same manner as the original appointments. Any non-federal member who is
appointed to fill the vacancy of an unexpired term shall be appointed
to serve for the remainder of that term.
Pursuant to advance written agreement, each non-federal member of
the Commission will waive his or her right to compensation for
performing services as a member of the Commission. However, non-federal
members shall receive per diem and reimbursement for travel expenses
incurred in relation to performing duties for the Commission, as
authorized by FACA and 5 U.S.C. 5703 for persons who are employed
intermittently to perform services for the Federal government and in
accordance with federal travel regulations. Ex-officio members of the
Commission remain covered under their current compensation system.
Estimated Number and Frequency of Meetings. The Commission shall
meet at least twice and not more than four times a year. These meetings
may be in person or conducted by teleconference or videoconference at
the discretion of the Designated Federal Official (DFO). The meetings
shall be open to the public, except as determined otherwise by the
Secretary, or other official to whom authority has been delegated, in
accordance with the guidelines under Government in the Sunshine Act, 5
U.S.C. 552b(c). Notice of all meetings shall be provided to the public
in accordance with the FACA. Meetings shall be conducted and records of
the proceedings shall be kept, as required by applicable laws and
departmental policies. A quorum is required for the Commission to meet
to conduct business. A quorum shall consist of a majority of the
Commission's voting members.
When the Secretary or designee determines that a meeting shall be
closed or partially closed to the public, in accordance with
stipulations of Government in the Sunshine Act, 5 U.S.C. 552b(c), then
a report shall be prepared by the DFO that includes, at a minimum, a
list of members and their business addresses, the Commission's
functions, date and place of the meeting, and a summary of the
Commission's activities and recommendations made
[[Page 18316]]
during the fiscal year. A copy of the report will be provided to the
Department's Committee Management Officer.
Nominations. Nominations, including self-nominations, of
individuals who have the specified expertise and knowledge will be
considered for appointment as members of the Commission. A nomination
should include, at a minimum, the following for each nominee: (1) A
letter of nomination that clearly states the name and affiliation of
the nominee, the basis for the nomination, and a statement from the
nominee that indicates that the individual is willing to serve as a
member of the Commission, if selected; (2) a one-page biography that
describes the nominee's qualifications and, if applicable, highlights
relevant experience on other federal advisory committees; (3) the
nominator's name, address, and daytime telephone number; and the
address, telephone number, and email address of the individual being
nominated; and (4) a current copy of the nominee's curriculum vitae or
resume, which should be limited to no more than 30 pages. Incomplete
nomination packages will not be reviewed.
Every effort will be made to ensure that the composition of the
Commission includes individuals from various geographic locations,
including rural and underserved areas; racial and ethnic minorities;
genders, and persons living with disabilities. Individuals other than
officers or employees of the United States government being considered
for appointment as members of the Commission will be required to
complete and submit a report of their financial holdings. An ethics
review must be conducted to ensure that individuals appointed as
members of the Commission are not involved in any activity that may
pose a potential conflict of interest for the official duties that are
to be performed. This is a federal ethics requirement that must be
satisfied upon entering the position and annually throughout the
established term of appointment on the Commission.
Authority: The National Clinical Care Commission Act (Pub. L.
115-80) requires establishment of the National Clinical Care
Commission. The Commission is governed by provisions of the Federal
Advisory Committee Act, Public Law 92-463, as amended (5 U.S.C.
App.), which sets forth standards for the formation and use of
federal advisory committees.
Dated: April 19, 2018.
Don Wright,
Deputy Assistant Secretary for Health (Disease Prevention and Health
Promotion).
[FR Doc. 2018-08797 Filed 4-25-18; 8:45 am]
BILLING CODE 4150-32-P
